United States Nanotechnology in Drug Delivery Market to Reach $61.08 Billion by 2030, Driven by Precision Medicine & Targeted Therapies

Leander, Texas and Tokyo, Japan - Dec.09.2025
As per DataM intelligence research report" Nanotechnology in Drug Delivery Market size was valued at US$ 51.4 billion in 2023 and is estimated to reach US$ 203.6 billion by 2030, growing at a CAGR of 17.9% during the forecast period (2024-2031)" Precision targeting and enhanced bioavailability are propelling nanotech-enabled drug delivery systems.

Download your exclusive sample report today: (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/nanotechnology-in-drug-delivery-market?Prasad

United States: Recent Industry Developments

✅ In November 2025, Pfizer announced a collaboration to develop next-gen lipid nanoparticles (LNPs) for gene editing. The new LNP design targets tissues beyond the liver, such as the lungs and muscle. It expands the therapeutic potential of mRNA medicines in the U.S.

✅ In October 2025, Arrowhead Pharmaceuticals presented data on a targeted RNAi delivery vehicle. The "TRiM" platform uses ligand-conjugated nanoparticles to silence disease genes. It demonstrates the precision of nanomedicine in treating U.S. patients with genetic disorders.

✅ In September 2025, a MIT spin-out launched a clinical trial for a nanoparticle-encapsulated chemotherapy. The formulation releases the drug only in the acidic environment of the tumor. It aims to reduce systemic toxicity for U.S. cancer patients.

✅ In August 2025, The FDA issued draft guidance on the quality attributes of nanomaterial-containing drug products. The document outlines testing requirements for particle size and surface charge. It provides a clearer regulatory path for U.S. nanotech drug developers.

Japan: Recent Industry Developments

✅ In December 2025, Fujifilm Corporation invested in a manufacturing site for liposomal drug formulations. The investment supports the production of "Doxil" generics and novel nano-drugs. It strengthens Japan's capability in complex injectable manufacturing.

✅ In November 2025, Nippon Kayaku received approval for a polymeric micelle drug for pancreatic cancer. The nanoparticle accumulates in tumor tissue via the EPR effect to enhance efficacy. It offers a new treatment option for a difficult cancer in Japan.

✅ In October 2025, Researchers at the University of Tokyo developed a "polymeric chaperone" nanoparticle. The particle prevents protein drugs from denaturing during delivery. It solves stability issues for biologic therapies in Japan.

✅ In September 2025, Shionogi partnered with a nano-tech startup to develop a nasal vaccine delivery system. The mucoadhesive nanoparticles deliver antigens across the nasal mucosa. It aims to create needle-free vaccines for the Japanese market.

Nanotechnology in Drug Delivery Market: Drivers
Nanotechnology in drug delivery is transforming pharmacology by enabling targeted delivery, improved bioavailability, and controlled release of therapeutics across oncology, CNS, and biologics. Liposomes, polymeric nanoparticles, lipid-based carriers, and nanocrystals help transport drugs across biological barriers while reducing systemic toxicity and enhancing therapeutic indices. Advances in surface functionalization, stimuli-responsive release, and scalable manufacturing are making nanomedicines more clinically viable. Regulatory pathways and robust characterization tools are evolving to address nanomaterial safety, batch consistency, and clinical performance.

Pharmaceutical companies are leveraging nanodelivery to revive hard-to-formulate molecules, enable RNA therapeutics, and improve targeted immunotherapies. Collaboration across material scientists, formulation experts, and clinical researchers accelerates translation from bench to bedside. With demonstrated success in vaccines and oncology, nanotechnology is poised to broaden its impact across multiple therapeutic areas supporting precision delivery and next-generation therapeutics.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/nanotechnology-in-drug-delivery-market?Prasad

Nanotechnology in Drug Delivery Market: Major Players
Ceramisphere Health Pvt Limited, Cristal Therapeutics, CYTIMMUNE SCIENCES, Inc., Nanobiotix, NanoCarrier Co. Ltd., NanOlogy LLC, EnColl Corporation, EyePoint Pharmaceuticals, AbbVie Inc., Aquanova AG, BlueWillow Biologics, Camurus AB, Celgene, Inc., Lena Nanoceutics Ltd.

Segment Covered in the Nanotechnology in Drug Delivery Market:
By Technology
The market is segmented into micelles 25%, nanoparticles 35%, liposomes 20%, nanocrystals 15%, and others 5%, with nanoparticles dominating due to enhanced bioavailability, targeted delivery, and widespread research applications. Micelles and liposomes are growing in oncology and anti-inflammatory therapies. Nanocrystals are used for poorly soluble drugs. Rising R&D investment and advanced formulation technologies drive adoption across all technologies.

By Applications
Applications include anti-infective 20%, neurology 15%, anti-inflammatory/immunology 20%, oncology 30%, cardiovascular/physiology 10%, and others 5%, with oncology dominating due to targeted cancer therapies and personalized medicine. Anti-infective and anti-inflammatory applications are growing with increasing global healthcare needs. Neurology and cardiovascular applications are gradually expanding. Broad therapeutic focus supports market growth across applications.

Regional Analysis
North America - 40% Share
North America leads with 40% share driven by strong pharmaceutical R&D, advanced healthcare infrastructure, and early adoption of nanotechnology in the U.S. and Canada. Nanoparticles dominate. Oncology and anti-infective applications are key. Pharmaceutical companies and research institutes are major end-users. Regulatory support and innovation drive market expansion.

Europe - 25% Share
Europe holds 25% share due to growing drug development initiatives, nanomedicine research, and healthcare infrastructure in Germany, UK, France, and Switzerland. Nanoparticles dominate. Oncology and anti-inflammatory applications lead adoption. Pharmaceutical and biotechnology companies drive market growth. Increasing clinical trials and government funding support expansion.

Asia Pacific - 20% Share
Asia Pacific accounts for 20% share driven by pharmaceutical growth, rising chronic disease prevalence, and investment in nanomedicine research in China, India, Japan, and Australia. Nanoparticles dominate. Oncology and anti-infective applications are major. Pharmaceutical and research institutes are key end-users. Healthcare modernization supports market adoption.

Latin America - 7% Share
Latin America holds 7% share due to growing pharmaceutical R&D, cancer research, and adoption of advanced drug delivery in Brazil, Mexico, and Argentina. Nanoparticles dominate. Oncology and anti-inflammatory applications lead. Pharmaceutical companies and hospitals are primary end-users. Regional research initiatives support growth.

Middle East - 5% Share
The Middle East records 5% share driven by investment in healthcare infrastructure, pharmaceutical innovation, and cancer research in UAE, Saudi Arabia, and Qatar. Nanoparticles dominate. Oncology and anti-infective applications are key. Pharmaceutical companies and research institutes lead adoption. Government funding and partnerships support market growth.

Africa - 3% Share
Africa holds 3% share due to emerging pharmaceutical research and limited nanomedicine adoption in South Africa, Nigeria, and Egypt. Nanoparticles dominate. Oncology and anti-inflammatory applications lead. Pharmaceutical companies and research institutes are primary end-users. Increasing awareness and investment drive gradual adoption.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=nanotechnology-in-drug-delivery-market
(Purchase 2 or more Repots and get 50% Discount)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?Prasad

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.